Sentences with phrase «other drug companies»

The patent on the human form of it expired a while back; this meant that other drug companies could produce it under its generic name, fluoxetine.

Also omitted from the LA Times article was that the two hormone experts, Stuenkel and Santoro both disclosed financial ties to Wyeth and other drug companies that make synthetic chemically altered «Monster»» hormones.

Former Vice President, Atiku Abubakar has spoken on the reopening of Emzor Pharmaceuticals and two other drug companies.

But what Sequoia married itself to was an offshore drug company that borrowed heavily to buy other drug companies, cut costs and research, then raised prices on many older drugs to astronomical heights.

More than other drug companies, it lives and dies by its pipeline.

The other thing that concerns me is when other drug companies like Pfizer, the ones that you may have in mind, are about to raise prices.

Sarissa also holds stakes in AbbVie, Biogen and Innoviva, among other drug companies.

Not exact matches

Made by companies like Gilead, AbbVie, Merck, and others, drugs that treat the disease are listed at tens of thousands of dollars in the U.S..

Cancer drug company Juno Therapeutics, which took in $ 145 million from Amazon's Jeff Bezos and other investors in 2014 is but one example.

«When you have a drug company up against a difficult disease that many others have failed to cure, be more skeptical.

So in the case of CVS, Meyer and his team first made sure that the company's decision to rebrand was warranted: Leaders wanted to push its image as a more health - focused alternative to other drug stores.

Other early seeds include the hot diabetes - drug company Intarcia Therapeutics (which I wrote about in November) and the Jonathan Bush - helmed athenahealth (now worth nearly $ 5 billion), which has become a prominent force in the age of the cloud - based doctor's office and hospital.

In other words, how much of each company's sales are coming from drugs fresh out of the pipeline versus how much are coming from older meds?

The company's results got a boost from higher sales of prescription drugs at its stores, among other factors.

Theranos» labs have been evaluated and deemed acceptable by drug companies, hospitals that work with them, Walgreens, and other entities.

Shkreli originally became infamous for his other former company Turing Pharma's 5,000 % price hike for a drug used by cancer and AIDS patients.

Valeant (TSX: VRX) said it had lost confidence in the Hatboro, Pa., - based company and was exploring relationships with other pharmacies to fill prescriptions for its drugs.

These risks and uncertainties include, among others: the unfavorable outcome of litigation, including so - called «Paragraph IV» litigation and other patent litigation, related to any of our products or products using our proprietary technologies, which may lead to competition from generic drug manufacturers; data from clinical trials may be interpreted by the FDA in different ways than we interpret it; the FDA may not agree with our regulatory approval strategies or components of our filings for our products, including our clinical trial designs, conduct and methodologies and, for ALKS 5461, evidence of efficacy and adequacy of bridging to buprenorphine; clinical development activities may not be completed on time or at all; the results of our clinical development activities may not be positive, or predictive of real - world results or of results in subsequent clinical trials; regulatory submissions may not occur or be submitted in a timely manner; the company and its licensees may not be able to continue to successfully commercialize their products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to governmental payers; the FDA or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading «Risk Factors» in the company's most recent Annual Report on Form 10 - K and in subsequent filings made by the company with the U.S. Securities and Exchange Commission («SEC»), which are available on the SEC's website at www.sec.gov.

Valeant, as the story unfolded, bought existing medications from other drug makers, as well as whole companies - then relentlessly hiked the prices of the drugs it acquired.

These rebates, struck between drug makers, pharmacy benefits managers, insurance companies, employers, and others, are largely negotiated in the background; but they don't necessarily trickle down to patients and consumers themselves.

The company has responded with statements saying that it's not as dependent on drug price increases as critics have claimed; it has also pointed out that while attention has focused on changes in list prices for drugs, those prices don't reflect the actual cost for insurers, governments and other group purchasers, which typically receive discounts that aren't publicly disclosed.

Food and Drug Administration Commissioner Scott Gottlieb decried what he called a «Kabuki» drug pricing construct between pharma companies, pharmacy benefits managers, insurers, and others during a health insurance confereDrug Administration Commissioner Scott Gottlieb decried what he called a «Kabuki» drug pricing construct between pharma companies, pharmacy benefits managers, insurers, and others during a health insurance conferedrug pricing construct between pharma companies, pharmacy benefits managers, insurers, and others during a health insurance conference.

Bristol - Myers emphasized Opdivo's other successes and ongoing studies evaluating its effectiveness in combination with the company's other cancer drugs.

Given its areas of specialization, Gilead wouldn't benefit as much from consolidation as, say, a generic - drug company would, but it still faces pricing pressure: To appease Medicaid and other insurers, Gilead is already steeply discounting its hep - C drugs, which can cost more than $ 80,000 for a 12 - week course.

By printing multiple lung airways — or any other afflicted organ — from a human patient and testing drugs on them, pharma companies can bypass the ethically challenged practice of testing on animals and proceed to human clinical trials with greater confidence the drugs will actually work, according to Wadsworth.

The company recently said it is going to pay $ 465 million to the Department of Justice and other government agencies over the way it classified the EpiPen in the Medicaid Drug Rebate Program.

And despite the fact that Mylan raised EpiPen prices roughly 30 % in 2015 while prescription volume also grew 7 %, the company's revenue on the drug actually fell slightly, as the other players took even bigger cuts, according to Raffat.

The Danish company said it would pay 28.00 euros per share in cash for Ablynx and an additional 2.50 euros in a so - called contingent value right (CVR) if certain conditions related to other drugs in Ablynx's research portfolio were met.

House and Senate Democrats have introduced legislation aimed at lowering drug prices through a series of aggressive measures, including by requiring biopharma companies to reveal far more information about their R&D, manufacturing, and other costs.

Importantly, the deal also means that Gilead / Kite rival Novartis (which had its own CAR - T drug approved ahead of Yescarta) and other CAR - T companies won't be able to get in on Sangamo's platform.

The company has developed an injectable liquid that turns solid when it enters the body to aid in (among other things) drug delivery; it's also invented a polymer - based artificial muscle — similar to Rajagopalan's abandoned PhD project — used in compression wear to counter pain.

Canada's grocery companies are in stiff competition against each other as well as other types of retailers that offer food items, including U.S. - based department store chain Walmart and Toronto - based Shoppers Drug Mart (TSX: SC).

Other changes announced on Friday include allowing US companies to provide safety - related services for commercial aircraft in Cuba, where US airlines are beginning regularly scheduled flights, and allow Cuban pharmaceutical companies to apply for US Food and Drug Administration approval.

It's possible that Paulson and Vanguard decided to invest their gains into other pharma companies developing new drugs, but they are just as likely to put their money somewhere else.

Perhaps this will include research and development of drugs for other diseases, albeit with fewer researchers, but to date, neither the amount the company will save nor its specific use of these freed - up resources has been detailed.

The Food and Drug Administration is deliberately preventing the public from getting natural cures for cancer and other diseases because of pressure from drug companDrug Administration is deliberately preventing the public from getting natural cures for cancer and other diseases because of pressure from drug compandrug companies.

By bringing a drug that's been well - established as safe in other markets to the U.S. for the first time in order to treat a rare disease, the company doesn't just control its pricing destiny — it will also receive a coveted «priority review voucher» which it can hawk to another firm for tens (or even hundreds) of millions of dollars.

Other Canadian companies such as WestJet, McCain Foods, Canadian Tire, Jean Coutu Group, Shoppers Drug Mart and Bombardier all made the Top 40.

That's an even rarer feat for a generic drug maker such as Mylan, which makes most of its revenue not on brand - name drugs, but on cheaper, equivalent versions of other companies» branded medications.

The health care sector consists of drug companies, medical supply companies, and other scientific - based operations that are concerned with improving and healing human life.

After years of buying up companies then raising the prices of their drugs — a strategy that rapidly amplified Valeant's revenue and stock price — Valeant is now struggling to grow by other means, while dealing with the consequences of its previous actions.

But on Tuesday, the Canadian company said it was expanding its sales force for Salix's key product, Xifaxin, among other drugs, suggesting plans to keep the business for the long term.

The pro forma information set forth in this News Release should not be considered to be what the actual financial position or other results of operations would have necessarily been had Loblaw and Shoppers Drug Mart operated as a single combined company as, at, or for the periods stated.

Two older mainstays among multiple - sclerosis drugs, made by other companies, have increased prices to seven times their 1990s levels to catch up with the prices of newcomers, researchers reported in April in the journal Neurology.

Other regulatory actions could come directly from Health and Human Services Secretary Alex Azar, a former drug company executive, and through the department's Centers for Medicare and Medicaid Services.

Why should we expect Mylan or any other pharmaceutical company to refrain from yanking up the price of lifesaving drugs as high as the market will bear?

Similarly, Mylan and other pharmaceutical companies can engage in price - gouging because they're the only ones producing these lifesaving drugs.

He specifically said Merck was manufacturing drugs abroad, even though he praised Merck last month for a new U.S. manufacturing initiative with two other companies.

The two companies plan to develop drugs to fight multiple cancer types, either alone or in combination with their other cancer treatments.

Companies that provide drug development and other product development services, equipment, software and services for research, manufacturing discovery and medical diagnostics.